{
  "company": {
    "ticker": "GILD",
    "name": "Gilead Sciences Inc.",
    "category": [
      "Biotech"
    ],
    "sector": "Healthcare",
    "subCategory": "Biotech",
    "cik": "0000882095"
  },
  "reports": [
    {
      "filing": {
        "accessionNumber": "0000882095-25-000047",
        "filingDate": "2025-11-07",
        "reportDate": "2025-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/gild-20250930.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 7769,
        "netIncome": 3052,
        "operatingCashFlow": 6692,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 56,
        "marketShareMention": "Successfully negotiated patent settlements with generic manufacturers for Biktarvy, extending exclusivity to 2035-2036",
        "customerConcentration": 60,
        "geographicBreakdown": {
          "US": 68,
          "Europe": 20,
          "RestOfWorld": 12
        },
        "capexAmount": 358,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma - STAT6 oral programs",
          "Galapagos - ongoing collaboration with potential entity separation"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent litigation with generic manufacturers",
          "Product liability lawsuits for HIV medications"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong Q3 performance with $7.8B revenue and $3.1B net income. Key highlights include successful patent defense for Biktarvy, strategic partnerships, and continued focus on innovative medicine development.",
        "keyQuotes": [
          "Successfully negotiated patent settlements extending Biktarvy exclusivity",
          "Continuing to invest in strategic collaborations like LEO Pharma partnership"
        ],
        "marketData": {}
      },
      "quarter": "Q3 2025",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2025,
        "fiscalQuarter": 3,
        "fiscalYear": 2025,
        "quarter": "Q3 2025",
        "reportDate": "2025-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-25-000032",
        "filingDate": "2025-08-07",
        "reportDate": "2025-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/gild-20250630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 7054,
        "netIncome": 1960,
        "operatingCashFlow": 2584,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Continue to lead in HIV market with Biktarvy",
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 71.4,
          "Europe": 16.7,
          "RestOfWorld": 11.9
        },
        "capexAmount": 211,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma strategic partnership for STAT6 program",
          "Ongoing collaboration with Galapagos",
          "Arcus Biosciences collaboration"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "FDA clinical hold on HIV treatment trials",
          "Ongoing patent litigation with generic manufacturers"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong Q2 2025 performance with robust HIV product sales, particularly Biktarvy. The company continues to invest in oncology and virology research while maintaining a disciplined approach to expenses and strategic partnerships.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "Received FDA approval for Yeztugo, the first and only twice-yearly HIV PrEP option"
        ],
        "marketData": {}
      },
      "quarter": "Q2 2025",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2025,
        "fiscalQuarter": 2,
        "fiscalYear": 2025,
        "quarter": "Q2 2025",
        "reportDate": "2025-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-25-000012",
        "filingDate": "2025-05-07",
        "reportDate": "2025-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/gild-20250331.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 6667,
        "netIncome": 1315,
        "operatingCashFlow": 1757,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 70,
          "Europe": 16,
          "RestOfWorld": 14
        },
        "capexAmount": 104,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma collaboration for STAT6 programs",
          "Galapagos partnership amendment",
          "Arcus Biosciences collaboration"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Medicare Part D program redesign impact",
          "Generic manufacturer patent challenges for Biktarvy"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered steady Q1 performance with flat revenues of $6.7B and a return to profitability at $1.3B net income. HIV and Liver Disease product sales showed growth, offsetting declines in COVID-related Veklury sales. The company continues strategic partnerships and maintains a confident outlook.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "Biktarvy sales increased primarily due to higher demand, including patients switching from Genvoya and other Gilead HIV products",
          "We regularly review our R&D activities based on unmet medical need"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2025",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2025,
        "fiscalQuarter": 1,
        "fiscalYear": 2025,
        "quarter": "Q1 2025",
        "reportDate": "2025-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000028",
        "filingDate": "2024-11-12",
        "reportDate": "2024-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/gild-20240930.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "not_provided",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 7545,
        "netIncome": 1253,
        "operatingCashFlow": 7853,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 72.2,
          "Europe": 15.5,
          "RestOfWorld": 12.3
        },
        "capexAmount": 376,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "Arcus collaboration",
          "CymaBay acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Trodelvy withdrawal for metastatic NSCLC",
          "Ongoing patent litigation with generic manufacturers"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "neutral",
        "summary": "Gilead reported quarterly revenue of $7.5B and net income of $1.25B, showing resilience despite challenges in its oncology pipeline. The company is restructuring its workforce and facing regulatory setbacks in the NSCLC indication, but maintains strong cash flow and continues strategic collaborations.",
        "keyQuotes": [
          "We recorded a partial impairment charge of $1.8 billion related to the NSCLC IPR&D intangible asset",
          "We incurred restructuring charges of $112 million primarily related to reductions in commercial and R&D workforce"
        ],
        "marketData": {}
      },
      "quarter": "Q3 2024",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2024,
        "fiscalQuarter": 3,
        "fiscalYear": 2024,
        "quarter": "Q3 2024",
        "reportDate": "2024-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000022",
        "filingDate": "2024-08-08",
        "reportDate": "2024-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/gild-20240630.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 6912,
        "netIncome": 1614,
        "operatingCashFlow": 3544,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 71.1,
          "Europe": 16.1,
          "RestOfWorld": 12.8
        },
        "capexAmount": 235,
        "capexGrowth": null,
        "partnerships": [
          "Merus N.V. research collaboration",
          "Xilio Therapeutics license agreement",
          "Janssen Pharmaceutica seladelpar royalty buy-out"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "FDA label expansions",
          "Ongoing patent litigation"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Gilead delivered solid Q2 results with 5% revenue growth driven by HIV, Oncology, and Liver Disease segments. The company continues to focus on strategic acquisitions like CymaBay while managing operating expenses and restructuring workforce.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "Completed the acquisition of CymaBay Therapeutics for $4.3 billion in total equity value"
        ],
        "marketData": {}
      },
      "quarter": "Q2 2024",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2024,
        "fiscalQuarter": 2,
        "fiscalYear": 2024,
        "quarter": "Q2 2024",
        "reportDate": "2024-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000013",
        "filingDate": "2024-05-08",
        "reportDate": "2024-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/gild-20240331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "lowered",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 6686,
        "netIncome": -4170,
        "operatingCashFlow": 2219,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 69.3,
          "Europe": 17.3,
          "RestOfWorld": 13.4
        },
        "capexAmount": 105,
        "capexGrowth": null,
        "partnerships": [
          "Research collaboration with Merus N.V.",
          "License agreement with Xilio Therapeutics",
          "Acquisition of CymaBay Therapeutics"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent litigation with generic manufacturers",
          "FDA approvals and label expansions"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": false,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Gilead faced significant financial challenges in Q1 2024, with a substantial net loss driven by large R&D charges related to CymaBay acquisition and Trodelvy impairment. HIV and Oncology segments showed modest growth, but the company is taking a cautious approach with workforce reductions.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "The decrease was primarily driven by an acquired in-process research and development charge of $3.9 billion related to the acquisition of CymaBay"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2024",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2024,
        "fiscalQuarter": 1,
        "fiscalYear": 2024,
        "quarter": "Q1 2024",
        "reportDate": "2024-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000007",
        "filingDate": "2024-02-23",
        "reportDate": "2023-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/gild-20231231.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 7149,
        "netIncome": 1463,
        "operatingCashFlow": 8006,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 71.6,
          "Europe": 15.9,
          "OtherInternational": 12.4
        },
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Assembly Biosciences",
          "Arcellx",
          "Compugen",
          "Tentarix",
          "Nurix Therapeutics"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Drug pricing pressures",
          "Medicare pricing negotiations",
          "State-level drug pricing reviews"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered solid financial performance in 2023, with total revenues of $27.1 billion and net income of $5.7 billion. Strong HIV and oncology product sales offset declining COVID-19 treatment revenues.",
        "keyQuotes": [
          "We continued to invest in our business and research and development pipeline through acquisitions and collaborations.",
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases."
        ],
        "marketData": {}
      },
      "quarter": "Q4 2023",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2023,
        "fiscalQuarter": 4,
        "fiscalYear": 2023,
        "quarter": "Q4 2023",
        "reportDate": "2023-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-23-000031",
        "filingDate": "2023-11-07",
        "reportDate": "2023-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/gild-20230930.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 7051,
        "netIncome": 2172,
        "operatingCashFlow": 5837,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 66,
        "geographicBreakdown": {
          "US": 71.1,
          "Europe": 14.8,
          "OtherInternational": 14.1
        },
        "capexAmount": 370,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "XinThera acquisition",
          "Tmunity acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Generic manufacturer patent challenges",
          "HIV antitrust litigation"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered solid Q3 2023 financial results with steady revenues of $7.05 billion and net income of $2.17 billion. The company continues to focus on strategic acquisitions and collaborations in oncology and cell therapy while defending its patent portfolio.",
        "keyQuotes": [
          "We, along with Janssen and Janssen Products, L.P., filed a patent infringement lawsuit against Lupin and Apotex",
          "We intend to enforce and defend our intellectual property"
        ],
        "marketData": {}
      },
      "quarter": "Q3 2023",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2023,
        "fiscalQuarter": 3,
        "fiscalYear": 2023,
        "quarter": "Q3 2023",
        "reportDate": "2023-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-23-000025",
        "filingDate": "2023-08-04",
        "reportDate": "2023-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/gild-20230630.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 6564,
        "netIncome": 1045,
        "operatingCashFlow": 4082,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": 103,
        "marketShareMention": null,
        "customerConcentration": 66,
        "geographicBreakdown": {
          "US": 72.7,
          "Europe": 15.1,
          "OtherInternational": 12.2
        },
        "capexAmount": 248,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "XinThera acquisition",
          "Tmunity acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "HIV antitrust litigation",
          "Patent challenges for sofosbuvir"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Gilead delivered steady Q2 2023 performance with $6.6B in revenue and $1.045B in net income. The company continues to focus on oncology and HIV product lines while managing ongoing patent and litigation challenges.",
        "keyQuotes": [
          "We continue to defend the strength of our intellectual property",
          "We are confident in our product portfolio and pipeline"
        ],
        "marketData": {}
      },
      "quarter": "Q2 2023",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2023,
        "fiscalQuarter": 2,
        "fiscalYear": 2023,
        "quarter": "Q2 2023",
        "reportDate": "2023-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-23-000017",
        "filingDate": "2023-05-03",
        "reportDate": "2023-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/gild-20230331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 6352,
        "netIncome": 985,
        "operatingCashFlow": 1744,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Strong performance in HIV and Oncology product sales",
        "customerConcentration": 64,
        "geographicBreakdown": {
          "US": 70.1,
          "Europe": 17,
          "OtherInternational": 12.9
        },
        "capexAmount": 109,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "Tmunity acquisition",
          "Nurix license for NX-0479",
          "AmerisourceBergen Corp",
          "Cardinal Health Inc",
          "McKesson Corp"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Various patent litigation proceedings",
          "Ongoing antitrust investigations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong Q1 2023 results with 13% HIV sales growth and 59% Oncology sales growth. The company continues to invest in R&D and strategic acquisitions while maintaining a solid financial position.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "We pursue and achieve breakthroughs in medicine for more than three decades"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2023",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2023,
        "fiscalQuarter": 1,
        "fiscalYear": 2023,
        "quarter": "Q1 2023",
        "reportDate": "2023-03-31"
      },
      "analyzedSuccessfully": true
    }
  ],
  "totalFetched": 12,
  "successfulAnalyses": 10,
  "lastUpdated": "2025-11-14T04:38:05.074Z"
}